0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Treatment of Parkinsonism: The Role of Dopa Decarboxylase Inhibitors

E. Richard Blonsky, MD
JAMA. 1973;225(7):755-756. doi:10.1001/jama.1973.03220340059041.
Text Size: A A A
Published online

ABSTRACT

The dopa decarboxylase inhibitors appeared on the scene at almost the same time as levodopa, but remained in the wings for a while as the latter became the major therapeutic tool in the treatment of parkinsonism. These agents have been of great interest to the physiologist, to the neurochemist, and to the clinician treating the parkinson patient. In the latter context, there are several problems that continue to beg for solution: the elimination of peripheral side effects resulting from levodopa administration (such as nausea and vomiting or orthostatic hypotension); a means of eliminating the "on and off" periods that interrupt a patient's daily function; and the elimination of the centrally mediated dyskinesias resulting from dopamine spillover in the basal ganglia. Many clinicians eagerly viewed the decarboxylase inhibitors as a solution to these problems, and in part this is true.

This book is the published report of a conference at Columbia

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();